New obesity drug ZT002 passes early safety check in 28 volunteers
NCT ID NCT06371326
First seen Jan 21, 2026 · Last updated May 13, 2026 · Updated 16 times
Summary
This early-stage study tested the safety and tolerability of a new injectable drug called ZT002 in 28 adults who were overweight or obese. Participants received either the drug or a placebo, and researchers monitored for side effects and how the drug moved through the body. The goal was to see if ZT002 is safe enough for further testing, not to measure weight loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERWEIGHT OR OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
First Affiliated Hospital of Bengbu Medical College
Bengbu, China
Conditions
Explore the condition pages connected to this study.